Thiyagarajan Saravanan - Integrative Immuno-Oncology Center, Mitra Biotech

基本信息

浏览量：13

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 60 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Abstract 3303: Paralogue Selective P300 Degraders Induce Synthetic Lethality in Pre-Clinical Models of CBP-deficient and P300-Dependent Malignancies

Saravanan Thiyagarajan,Chandrasekhar Abbineni,Krishna Chaitanya T,Achala Apte,Iram Khan Iqbal,Naveen Kumar R,Aravind A B,Avinash Kumar, Dabbeeru Madhu Babu, Shwetha, Ankita Manna, Monalisha Mandal, Rituparna Panigrahi,Sivapriya Marappan,Suraj T Gore, Mohamad Fairus, Lim Yang Jin,Subhendu Mukherjee,Girish Daginakatte,Shekar Chelur, Kavitha Nellore,Murali Ramachandra,Susanta Samajdar

Cancer Researchno. 6_Supplement (2024): 3303-3303

引用0浏览0引用

Abstract 6065: Identification and Characterization of Paralogue Selective CBP Degraders for Potential Use in Cancer Therapy

Saravanan Thiyagarajan,Chandrasekhar Abbineni,Krishna T. Chaitanya,Achala Apte,Iram Khan Iqbal,Naveen R. Kumar,A. B. Aravind,Avinash Kumar,A. R. Girish, Aishwarya B. Kamath, Deepak Dattatray Mane, Gouri A. Raj, Reshma Reghu, Subhasmita Mohapatra,Sivapriya Marappan,Suraj T. Gore,Subhendu Mukherjee,Girish Daginakatte,Kavitha Nellore,Shekar Chelur,Murali Ramachandra,Susanta Samajdar

CANCER RESEARCHno. 6 (2024)

引用0浏览0引用

Discovery of Potent and Paralog Selective PROTAC Degraders of CBP or P300 Proteins for the Treatment of Various Cancers

Chandrasekhar Abbineni,Saravanan Thiyagarajan,Krishna T. Chaitanya,Achala Apte, Naveen R. Kumar,Avinash Kumar, Dabbeeru Madhu Babu, S. Shwetha, Aishwarya B. Kamath, Monalisha Mandel, Rituparna Panigrahi,Sivapriya Marappan,Subhendu Mukherjee, Kavitha Nellore,Shekar Chelur,Murali Ramachandra,Susanta Samajdar

MOLECULAR CANCER THERAPEUTICSno. 12 (2023)

引用0浏览0引用

Abstract 4030: Generation of Profound Anti-Tumor Immunity by AUR-109, a Spectrum-Selective Tyrosine Kinase Inhibitor, Either As a Single Agent or in Combination with Immune Checkpoint Inhibitors

Girish Daginakatte,Saravanan Thiyagarajan,Kiran Aithal,Mamon Dey, Reshma Reghu, Monalisha Mandal, Kavitha Nellore,Susanta Samajdar,Murali Ramachandra

Cancer Researchno. 7_Supplement (2023): 4030-4030

引用0浏览0引用

P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES

Manjunath Krishnappa, Divyesh Mandavia,Minish Jain, Srivastava Mukesh, Ankit Patel, Aditi Agarwal,Sanjeev Giri,Nirbhay Kumar Tiwari,Saravanan Thiyagarajan,Mamon Dey, Gsrsnk Naidu,Murali Ramachandra, Akhil Kumar

HemaSphereno. S3 (2023): e183727f-e183727f

引用0浏览0引用

1313 Characterization of the Anti-Tumor Immune Activation Potential of AUR107, a Novel Small Molecule P300/cbp Bromodomain Inhibitor

Girish Daginakatte,Chandrasekhar Abbineni,Saravanan Thiyagarajan,Mamon Dey, Aravind Basavaraj,Amit Dhudashiya,Sivapriya Marappan,Sandeep Sadashiv Patil,Naveen R. Kumar, N. R. Raghavendra,Avinash Kumar, Uma B. Bharathi,Girish Renukappa,Venkata Siva Reddy,A. Amith, C. S. Lavanya,Subhendu Mukherjee,D. S. Samiulla,Thomas Antony,Rajesh Eswarappa,Kavitha Nellore,Shekar Chelur,Murali Ramachandra,Susanta Samajdar

Regular and Young Investigator Award Abstracts (2022)

引用0浏览0引用

Abstract 4114: Evaluation of AU-18069, a Novel Small Molecule CBP/p300 Bromodomain Inhibitor for the Treatment of Cancers

Cancer researchno. 12_Supplement (2022): 4114-4114

引用0浏览0引用

Systems biology informed neural networks (SBINN) predict response and novel combinations for PD-1 checkpoint blockade

Michelle Przedborski,Munisha Smalley,Saravanan Thiyagarajan,Aaron Goldman,Mohammad Kohandel

COMMUNICATIONS BIOLOGY（2021）

引用7浏览0WOSNATURE引用

Abstract 1143: Evaluation of AU-18069, a Novel Small Molecule CBP/p300 Bromodomain Inhibitor for the Treatment of Cancers

Cancer researchno. 13_Supplement (2021): 1143-1143

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn